STUDY OBJECTIVE: The lower limit for the baseline value to initiate methacholine bronchial hyperresponsiveness testing has not been well established. Recommendations have varied from > 1 L to above 80% of predicted. The objective was to determine if an FEV1 < 60% predicted was acceptable. DESIGN: Retrospective analysis of challenges in 88 patients with a baseline FEV1 of < 60% predicted (mean=45.8%; range, 22 to 59%. SETTING: Academic institutions. RESULTS: There were only four individuals whose FEV1 did not return to > 90% of baseline following one poststudy beta2-agonist treatment. All four responded to a second treatment. There were no adverse sequelae following challenge in any individual. Neither age (up to 79 years) nor gender influenced outcome. CONCLUSIONS: In chronic moderate to severe asthma, it appears that bronchial hyperresponsiveness testing can be safely performed even in those patients with a low baseline FEV1.
STUDY OBJECTIVE: The lower limit for the baseline value to initiate methacholinebronchial hyperresponsiveness testing has not been well established. Recommendations have varied from > 1 L to above 80% of predicted. The objective was to determine if an FEV1 < 60% predicted was acceptable. DESIGN: Retrospective analysis of challenges in 88 patients with a baseline FEV1 of < 60% predicted (mean=45.8%; range, 22 to 59%. SETTING: Academic institutions. RESULTS: There were only four individuals whose FEV1 did not return to > 90% of baseline following one poststudy beta2-agonist treatment. All four responded to a second treatment. There were no adverse sequelae following challenge in any individual. Neither age (up to 79 years) nor gender influenced outcome. CONCLUSIONS: In chronic moderate to severe asthma, it appears that bronchial hyperresponsiveness testing can be safely performed even in those patients with a low baseline FEV1.
Authors: Mihaela Teodorescu; Oleg Broytman; Douglas Curran-Everett; Ronald L Sorkness; Gina Crisafi; Eugene R Bleecker; Serpil Erzurum; Benjamin M Gaston; Sally E Wenzel; Nizar N Jarjour Journal: J Allergy Clin Immunol Pract Date: 2015-05-21
Authors: Robert S Tepper; Robert S Wise; Ronina Covar; Charles G Irvin; Carolyn M Kercsmar; Monica Kraft; Mark C Liu; George T O'Connor; Stephen P Peters; Ronald Sorkness; Alkis Togias Journal: J Allergy Clin Immunol Date: 2012-03 Impact factor: 10.793
Authors: William W Busse; Adam Wanner; Kenneth Adams; Herbert Y Reynolds; Mario Castro; Badrul Chowdhury; Monica Kraft; Robert J Levine; Stephen P Peters; Eugene J Sullivan Journal: Am J Respir Crit Care Med Date: 2005-07-14 Impact factor: 21.405
Authors: Michael D Cabana; Susan J Kunselman; Sharmilee M Nyenhuis; Michael E Wechsler Journal: J Allergy Clin Immunol Date: 2014-01 Impact factor: 10.793